New in CME Courses: Non-Small Cell Lung Cancer: Optimizing Systemic Therapy Options Beyond the 1st Line

Target audience:  Oncologists, oncology nurses, pathologists, radiologists, pharmacists, and other healthcare practitioners who care for patients with lung cancer.

Disease Progression After First Line Therapy

Patients refractory to first-line therapy have a particularly poor prognosis and present as a challenging population for the clinician. The understanding that tumor histology, tumor genetic alterations, response to first line therapy and patient presentation all influence treatment choice provides the oncologist with more data available than ever available to optimize therapy. The ongoing development of biomarkers to assist in these treatment decisions has added additional complexity to the management of patients who have progressed through first line therapy.

This activity utilizes interactive cases, data reviews, and faculty feedback to build upon your current knowledge of data and recommendations for patients with NSCLC who have progressed on first line therapy, with the goal of enhancing the application of this knowledge into current clinical practice.

This activity – Non-Small Cell Lung Cancer: Optimizing Systemic Therapy Options Beyond the 1st Line, offers: .50 AMA PRA Category 1 Credit™, .50 ANCC contact hours.

Click here to start this activity!